Branaplam was initially designed for spinal muscular atrophy (SMA) and promotes inclusion of exon 7 in the SMN2 transcript via stabilization of the pre-mRNA - U1 snRNP complex8. Here, SMN2 is linked to proximal spinal muscular atrophy.